Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.60 -1.08 (-2.21%)
Streaming Delayed Price Updated: 3:14 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗
Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children. 
Via Investor's Business Daily
Topics Death
News headline image
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗
The comeback may have begun. 
Via The Motley Fool
News headline image
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation ↗
Sanofi stock dropped Wednesday after French authorities raided the firm's headquarters as part of a tax fraud investigation. 
Via Investor's Business Daily
Topics Fraud
News headline image
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This... 
Via TokenRing AI
Topics Artificial Intelligence Economy Product Recall
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Roche Holding Stock Popped Today ↗
Roche is great at developing drugs -- but is its stock a great buy? 
Via The Motley Fool
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics. 
Via Investor's Business Daily
News headline image
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗
Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%. 
Via Investor's Business Daily
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales. 
Via Benzinga
News headline image
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care 
From Medidata Solutions, Inc.
Via GlobeNewswire
News headline image
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,... 
Via MarketMinute
Topics Government World Trade
News headline image
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark ↗
Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth expected. 
Via Benzinga
Topics Earnings
News headline image
Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion ↗
Sanofi stock jumped early Friday on better-than-expected quarterly sales. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For October 24, 2025 ↗
 
Via Benzinga
News headline image
Oil Stocks Rally On Trump's Russia Sanctions: What's Moving Markets Thursday? ↗
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp rebound in crude prices and lifted energy shares. 
Via Benzinga
Topics Government
News headline image
Examining the Future: Sanofi's Earnings Outlook ↗
 
Via Benzinga
News headline image
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care 
From Medidata Solutions, Inc.
Via GlobeNewswire
News headline image
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy ↗
Sanofi revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101). 
Via Benzinga
News headline image
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the... 
Via MarketMinute
News headline image
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease ↗
CHMP rejects Sanofi's Rezurock for chronic GVHD in the EU, while approving Wayrilz for ITP, highlighting mixed outcomes for new treatments. 
Via Benzinga
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent. 
Via Investor's Business Daily
News headline image
Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study ↗
Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic neuroendocrine tumors. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.